We are excited to announce that BARDA is partnering with Cytokind's team to expand its clinical trial to further validate a phototherapy device. Our grant award is the first non-pharmacological therapeutic to be given in an effort to support BARDA's Division of Research, Innovation, and Ventures (DRIVe). The awards announced are part of BARDA DRIVe's medical countermeasure portfolio.
LATEST RESEARCH UPDATE
THE TEAM
LEADERS IN UVB LIGHT RESEARCH AND ASSOCIATED BLOOD ANALYSIS TO TREAT IMMUNE DISORDERS
Cytokind’s team includes pre-eminent scientific innovators, entrepreneurs, world-class researchers, and drug discovery visionaries from Stanford, MIT, Mt. Sinai, Australia, Austria, Scotland, Germany, Louisiana, Texas, and Wisconsin who are leaders in UVB light research and associated blood analysis to treat immune disorders.
These esteemed thinkers and innovators will help us on our path to discover new methods of treatment and drug discovery to address the critical needs of patients in the US and around the world.
Phototherapy
FACTS ABOUT UV LIGHT
UV Light & Our Biology
The impact of UV Light on our biology is so important that it is broken into 3 distinct spectrums (UVA, UVB and UVC).
UVB
We are focused on the immune-modulating properties of UVB.
UVB Stabilizes Our Immune System
Our Immune system hungers for UV light - "Following exposure of humans to sunlight to phototherapy, there are alterations in the number, phenotype and function of circulating blood cells."
LEARN MORE
LEARN MORE
Sunlight Extends Longevity
Avoidance of sun exposure is a risk factor for major causes of death: a 20-year study of 39,973 adults in Sweden
LEARN MORE
LEARN MORE
Natural Sunlight and UV Treatment in MS
Natural Sunlight Reduces MS Prevalence, Risk, and Severity - LEARN MORE
UV Treatment in the Clinic Reduces Relapses by 30% - LEARN MORE
UV Treatment in the Clinic Reduces Relapses by 30% - LEARN MORE
UVB Treatment ≠ to Melanoma
"Multiple studies specifically assessing the carcinogenic potential of NB-UVB did not find an increased risk of skin cancer in treated patients. Unfortunately, there are few prospective studies assessing the risk of skin cancer in patients with psoriasis treated with NB-UVB. Because of the theoretical possibility of this risk, physicians should use caution in prescribing NB-UVB for patients with a history of melanoma, multiple nonmelanoma skin cancers, arsenic intake, or exposure to ionizing radiation." From The Joint American American Academy of Dermatology 2019
LEARN MORE
LEARN MORE
